Provided by Tiger Trade Technology Pte. Ltd.

PolyPid Ltd.

4.98
-0.1240-2.43%
Volume:117.59K
Turnover:601.34K
Market Cap:101.07M
PE:-3.37
High:5.18
Open:5.12
Low:4.98
Close:5.10
52wk High:5.73
52wk Low:3.06
Shares:20.31M
Float Shares:12.16M
Volume Ratio:0.84
T/O Rate:0.97%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4762
EPS(LYR):-2.0900
ROE:-243.59%
ROA:-74.63%
PB:18.76
PE(LYR):-2.38

Loading ...

PolyPid Q1 FY26 net loss narrows 7.61% to $7.7 million

Reuters
·
May 13

PolyPid Q1 EPS $(0.35) Beats $(0.43) Estimate

Benzinga Earnings
·
May 13

PolyPid Ltd - U.S. Commercial Partnership Discussions for D-Plex100 in Late Stages

THOMSON REUTERS
·
May 13

Press Release: PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results

Dow Jones
·
May 13

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 13

PolyPid Ltd expected to post a loss of 43 cents a share - Earnings Preview

Reuters
·
May 11

PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026

GlobeNewswire
·
May 06

PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting

GlobeNewswire
·
Apr 28

Roth MKM Remains a Buy on PolyPid (PYPD)

TIPRANKS
·
Apr 15

PolyPid says SHIELD II data show D-PLEX100 doxycycline release lasts up to 32 days

Reuters
·
Apr 13

PolyPid starts trading on Frankfurt Stock Exchange under 2PV, adding to Nasdaq listing

Reuters
·
Apr 08

PolyPid director Yitzhak Jacobovitz files initial beneficial ownership statement

Reuters
·
Apr 07

PolyPid files Form 3 disclosing director Robert Benjamin Stein holdings

Reuters
·
Apr 06

PolyPid Begins FDA NDA Submission for D-PLEX₁₀₀ to Prevent Surgical Infections

TIPRANKS
·
Apr 01

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Mar 31

PolyPid’s Moment Is Here: NDA Submission Begins as a High-Impact Catalyst Stack Takes Shape (NASDAQ: PYPD)

TIPRANKS
·
Mar 31

BRIEF-Polypid Initiates D-Plex₁₀₀ NDA Submission To The FDA

Reuters
·
Mar 31

PolyPid Ltd - U.S. Commercialization Partnership Negotiations for D-Plex₁₀₀ on Track

THOMSON REUTERS
·
Mar 31

PolyPid Initiates D-Plex₁₀₀ Nda Submission to the FDA

THOMSON REUTERS
·
Mar 31

PolyPid Ltd - Nda Submitted Under FDA Fast Track Designation; Clinical Section Expected Q2 2026

THOMSON REUTERS
·
Mar 31